Holen Sie sich die Stockscreener-App
9.905
6.71%
0.585
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
What drives Elicio Therapeutics Inc. stock priceOutstanding stock performance - Autocar Professional
What analysts say about Elicio Therapeutics Inc. stockConsistent high-performance stocks - jammulinksnews.com
When the Price of (ELTX) Talks, People Listen - news.stocktradersdaily.com
Is Elicio Therapeutics Inc. a good long term investmentExponential wealth increase - jammulinksnews.com
How Elicio Therapeutics Inc. stock performs during market volatilityWeekly Double Return List - Newser
Elicio Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Elicio Therapeutics: Promising Trial Results and Commercial Potential Drive Buy Rating - TipRanks
H.C. Wainwright raises Elicio Therapeutics stock price target to $13 on trial outlook By Investing.com - Investing.com South Africa
H.C. Wainwright raises Elicio Therapeutics stock price target to $13 on trial outlook - Investing.com Australia
Elicio Therapeutics: HC Wainwright Raises PT to $13, Maintains Buy Rating - AInvest
What makes Elicio Therapeutics Inc. stock price move sharplyFree Signals Group - Newser
Why Elicio Therapeutics Inc. stock attracts strong analyst attentionTop Performer Shortlist - Newser
Trend Tracker for (ELTX) - news.stocktradersdaily.com
Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) market cap up US$12m last week, benefiting both retail investors who own 47% as well as insiders - simplywall.st
When (ELTX) Moves Investors should Listen - news.stocktradersdaily.com
Elicio Therapeutics, Inc.(NasdaqCM: ELTX) dropped from Russell 3000E Growth Index - MarketScreener
JonesTrading Remains a Buy on Elicio Therapeutics (ELTX) - The Globe and Mail
Is Elicio Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Elicio Therapeutics Secures Strategic Financing As Pivotal Cancer Trial Data Approaches - Barchart.com
Elicio Therapeutics to Host Virtual KOL Event on June 25, - GlobeNewswire
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewswire Inc.
Elicio secures $10 million to extend cash runway By Investing.com - Investing.com South Africa
Elicio Therapeutics Secures $10 Million in Financing - citybiz
Elicio Therapeutics Gets $10 Million Note Financing - marketscreener.com
Elicio secures $10 million to extend cash runway - Investing.com
Elicio Therapeutics Secures $10M Financing for Operations - TipRanks
Elicio Therapeutics (ELTX) Secures $10M Financing to Extend Operations | ELTX Stock News - GuruFocus
Elicio Therapeutics Lands $10M Funding to Advance Revolutionary Cancer Vaccine Through Critical Trial Phase - Stock Titan
Elicio Therapeutics announces board election results By Investing.com - Investing.com Nigeria
Elicio Therapeutics Elects New Directors at Annual Meeting - TipRanks
Elicio Therapeutics announces board election results - Investing.com
Elicio Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Elicio's (ELTX) ELI-002 Interim Analysis Anticipated in Phase 2 Trial | ELTX Stock News - GuruFocus
Elicio Therapeutics: Q1 Earnings Snapshot - CTPost
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
3.81%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):